A PAIR of teams at Basingstoke hospital have been commended for their work toward a study.

The haemophilia and research and development teams at Basingstoke hospital have been commended by the NIHR Clinical Research Network for recruiting the first patient to a global study looking at therapy used to treat patients with Haemophilia A.

Haemophilia is a rare condition that affects the blood’s ability to clot.

The research study, which will last between six and 12 months, is looking at what people with Haemophilia A use to control or treat their disease.

The current therapy used helps to reduce bleeding and the associated problems, including long term joint damage and pain, by replacing the missing clotting factor in the blood.

However, to prevent bleeds, most patients have to take the solution through an IV every other day, which can often place a huge burden on patients, as well as being a costly treatment.

The second phase of the study will test a new version of the therapy, which will mean patients can reduce the number of treatments needed, improving their quality of life.

For first patient Phil Wheeler, being part of this first phase will mean he is eligible for the second phase of the study, which the team hopes to begin later in the year.

Phil said: “Being part of this study gives me hope for both my own future and for younger haemophiliacs.”

Alex Whitfield, chief executive of Hampshire Hospitals, said: “Research and collaboration are key in our trust and it is fantastic to see these two principles working hand-in-hand.

“Studies like this are hugely important so that we can continue to deliver the best possible care to our patients, whilst also providing our staff with learning and development opportunities.

“I am exceptionally proud of all of our staff who were involved.”